Jun 13, 2020
EHA25Virtual: Adult Patients With Sickle Cell Disease May Be at Increased Risk of Adverse Outcomes From COVID-19
Jan 06, 2020
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis
Nov 15, 2019
Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
Nov 07, 2019
Rigel Announces Upcoming Data Presentations at the 61st ASH Annual Meeting & Exposition
Nov 06, 2019
New data to be presented at ASH 2019 highlight Sanofi's commitment to treat challenging blood cancers and rare blood disorders
Oct 29, 2019
Disc Medicine Expands Pipeline Focused on Hepcidin Pathway
Oct 18, 2019
Rigel Receives Positive Trend Vote from CHMP for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
Apr 25, 2019
The Worldwide Market for Anemia Treatment Drugs to 2026 - The Overall Competitive Scenario is Expected to Observe a Paradigm Shift Towards Gene Therapy & Monoclonal Antibody Therapies
Jan 09, 2019
Global Hereditary Hematological Disorders Drug Development Report 2018
Oct 29, 2018
Rigel Pharmaceuticals Enters Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. to Develop and Commercialize TAVALISSE(TM) (fostamatinib disodium hexahydrate) in Japan and other Asian Countries
Oct 11, 2018
Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients
Sep 27, 2018
Rigel to Host Investor & Analyst Day in New York City on October 4, 2018
Dec 08, 2017
Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annual Meeting
Oct 18, 2017
Global Hematological Disorders Market 2017 - Innovative First-in-Class Product Developments Remain Attractive
May 31, 2017
Hemophilia A Therapeutics Pipeline (Hematological Disorders) Review H1 2017 Market Report